The Evolution and Impact of Patient Support Services: A Strategic Framework

Patient support programs (PSPs), commonly referred to as "hub services" in the pharmaceutical industry, have evolved from simple reimbursement assistance into comprehensive, strategic initiatives that address the complex barriers patients face when accessing and adhering to specialty medications.

This article examines the current state of patient support services, their critical components, measurable outcomes, and strategic implications for pharmaceutical manufacturers, specialty pharmacies, and healthcare systems.

Drawing from real-world evidence and published research, this analysis demonstrates that well-designed patient support programs deliver measurable value across multiple dimensions: improving medication adherence by 29%, reducing healthcare costs by up to 29%, and significantly lowering discontinuation rates. As 90% of novel drugs launched in 2019 included manufacturer-sponsored patient services, these programs have become an industry standard rather than a competitive differentiator.

The Medication Adherence Crisis

Medication nonadherence represents one of the most significant challenges facing healthcare systems globally. Between 30-50% of medications prescribed for adults with chronic illnesses are not taken as prescribed.¹ This widespread problem contributes to approximately 125,000 deaths annually in the United States and accounts for 10% of hospitalizations. The economic burden is staggering, with nonadherence contributing an estimated $100-$290 billion in avoidable healthcare costs each year.²

The drivers of nonadherence are multifactorial and complex. Commonly cited barriers include forgetfulness, concerns about drug side effects, medication costs, inability to obtain or pick up prescriptions, beliefs that medication is unnecessary, and lack of knowledge about proper medication use.³ For biologic therapies used in chronic autoimmune diseases, nonadherence rates range from 28-52%, significantly higher than the 25% average across all medication classes.⁴

This adherence crisis occurs against the backdrop of an aging population and rising prevalence of chronic diseases. Between 2010-2019, pharmaceutical companies developed thirty-eight new specialty drugs to treat chronic diseases—a 60% increase from the previous decade. As medications become increasingly complex, requiring special handling, administration support, and monitoring, traditional healthcare delivery models prove insufficient to ensure optimal patient outcomes.

What Is the Strategic Rationale for Patient Support Programs?

From Volume to Value-Based Care

The US healthcare system is undergoing a fundamental transformation from volume-based to value-based care. This shift, accelerated by the Medicare Improvements for Patients and Providers Act (2008) and the Affordable Care Act (2010), emphasizes patient-centered approaches, improved health outcomes, and population health management.⁵ Patient support programs align directly with these value-based care objectives by addressing the three main pillars: greater patient satisfaction, better health outcomes, and improved overall population health.

For pharmaceutical manufacturers, this transition presents both challenges and opportunities. Traditional commercial models focused primarily on physician engagement and drug promotion. However, as payers increasingly demand evidence of real-world effectiveness and cost-efficiency, manufacturers must demonstrate that their products deliver value beyond the molecule itself. Patient support programs provide this differentiation by ensuring patients can access, afford, and appropriately use therapies to achieve optimal clinical outcomes.

What Is the Business Case for Comprehensive Support?

Life sciences consulting firms explicitly recommend that drug manufacturers include patient services as part of their commercialization strategy.⁶ Patient support services are now recognized as having "significant impact on overall brand and patient experience," directly influencing commercial success.⁷ This is particularly critical for specialty medications, where successful patient access can determine product viability in the marketplace.

The business rationale rests on several key factors:

Market access complexity: Specialty medications face dual barriers of prohibitive costs and complex insurance requirements including prior authorization and step therapy. These utilization management tools, while intended to control costs, create substantial administrative burden for prescribers and potential delays or denials for patients. Patient support programs that streamline these processes reduce abandonment rates and facilitate therapy initiation.

Adherence-driven demand: Unlike acute medications where non-adherence primarily affects individual patient outcomes, chronic disease therapies require sustained adherence to generate clinical benefit and commercial success. A patient who discontinues therapy after three months represents lost revenue, unfulfilled clinical promise, and potential negative real-world evidence. Programs that improve persistence directly impact product lifecycle value.

Competitive differentiation: As the number of treatment options within therapeutic categories expands, patient support services become a meaningful point of differentiation. Comprehensive programs that reduce patient burden and improve the treatment experience can influence prescriber preference and patient choice, particularly when clinical efficacy across options is similar.

Stakeholder alignment: Patient support programs represent one area where interests of multiple stakeholders genuinely align. Patients benefit from reduced out-of-pocket costs and better health outcomes. Prescribers appreciate reduced administrative burden and improved patient outcomes. Payers, while sometimes skeptical, benefit from reduced medical costs associated with better disease management. Manufacturers gain increased utilization and stronger stakeholder relationships.

The Anatomy of Patient Support Programs: Core Components

Analysis of patient support programs reveals four primary service categories that address distinct dimensions of patient access barriers:

Clinical Support Services

Clinical support services address barriers related to disease understanding, treatment complexity, and medication administration. These services typically include:

Patient education and counseling (40% of programs): Comprehensive disease state education, treatment guidance, symptom management, and lifestyle modification counseling. Education may be delivered through multiple channels including printed materials, digital resources, one-on-one counseling, and group education sessions.

Clinician hotlines (13% of programs): Dedicated phone lines staffed by pharmacists or nurses who can answer patient questions about their therapy at any time. Some programs offer 24/7 availability, providing patients with rapid access to clinical expertise when concerns arise.

In-home clinical support (5% of programs): For complex therapies requiring specialized administration techniques, clinical educators provide in-home training on self-injection, device use, and therapy management. This firsthand support is particularly valuable for biologic therapies requiring reconstitution or specialized injection techniques.

Free samples and bridge therapy (20% of programs): Samples provided to prescribers or direct bridge supply to patients help eliminate gaps between prescription and insurance approval, ensuring therapy continuity during the authorization process.

Connection to third-party resources (7.5% of programs): Referrals to patient advocacy groups, support communities, counseling services, and organizations providing transportation or lodging assistance for treatment-related appointments.

Real-world evidence demonstrates the impact of clinical support. In a comprehensive study of adalimumab patients, those enrolled in a patient support program featuring dedicated nurse ambassadors showed 29% higher medication adherence (64.8% vs 50.1%) compared to non-participants.⁸ The program included disease and product education, drug access support, temperature maintenance resources, and medication reminders through multiple channels.

Case Management Services

Case management programs (38% of novel drugs) represent the most comprehensive form of patient support, integrating multiple services under coordinated care delivery. Upon enrollment, patients are assigned a dedicated case manager who serves as a single point of contact throughout the treatment journey.

Case managers typically provide:

• Benefits investigation to determine insurance eligibility and coverage.
• Prior authorization support and appeals assistance.
• Treatment education and medication counseling
• Medication dispenses coordination and delivery support.
• Routine check-in calls to assess adherence and address concerns.
• Appointment reminder calls to reduce missed visits.
• Care coordination with healthcare providers and practices.

This end-to-end support model addresses the reality that patients face multiple, interconnected barriers simultaneously. A patient struggling with insurance authorization may also need education about their disease and reminders to take medication consistently. Case management programs recognize these interrelationships and provide holistic support.

The effectiveness of case management is evidenced by improved continuity of care and reduced treatment gaps. Programs offering coordinated support show significantly lower discontinuation rates—in one study, 22% lower than non-participants (51.4% vs 65.9%)—indicating that comprehensive support helps patients persist through the critical initial treatment phase.⁸

Financial Support Programs

Financial support represents the most prevalent service category, with 80% of novel drugs providing copayment assistance or patient assistance programs. This prevalence reflects the reality that cost remains a primary barrier to medication access and adherence, particularly for specialty medications with list prices ranging from hundreds to hundreds of thousands of dollars monthly.

Copayment and coinsurance assistance (80% of programs): For commercially insured patients, copayment programs reduce out-of-pocket costs to between $0-$20 per month. Manufacturers typically cap annual support at predetermined amounts. These programs help insulate patients from cost-related nonadherence while maintaining adherence to prescribed therapy.

Patient assistance programs (80% of programs): For uninsured or underinsured patients, separate nonprofit entities (often affiliated with manufacturers) provide medications at no cost. These programs typically require income verification and operate under strict regulatory guidelines to ensure appropriate use.

Benefits investigation and navigation (60% of programs): Services that determine patient insurance eligibility, identify coverage limitations, and navigate utilization restrictions including prior authorization and step therapy requirements. This proactive benefits verification enables early identification of access barriers and development of mitigation strategies.

Prior authorization and appeals support (35% of programs): Assistance for healthcare providers in obtaining insurance approvals and filing appeals when coverage is denied. This includes providing template letters, clinical documentation support, and guidance on payer-specific requirements.

Reimbursement specialists (15% of programs): Field-based personnel who educate physicians and practice billing and coding requirements, documentation standards, and payer policies specific to medication. This support is particularly valuable for physician-administered products requiring separate reimbursement for the drug and administration.

Online physician portals (20% of programs): Digital platforms enabling prescribers to simultaneously enroll patients, initiate benefits investigations, submit prior authorization documents, and track progress. These streamlined workflows reduce administrative burden and accelerate time to therapy.

The impact of financial support extends beyond the direct cost savings to patients. A study of multiple sclerosis patients found that comprehensive patient support programs were associated with reduced MS-related hospitalization risk and decreased MS-related medication costs over time.⁹ This suggests that removing financial barriers enables more consistent therapy use, which translates to better disease management and reduced downstream medical costs.

Technology Solutions

Technology platforms (20% for physician portals, 8% for mobile applications) represent the newest category of patient support services. These digital tools aim to enhance convenience, improve communication, and provide real-time support.

Technology solutions include:

• Mobile applications for patients to track symptoms, medication administration, and communicate with support teams.
• Physician portals for streamlined program enrollment and benefits verification.
• Mobile ordering applications for prescribers to order inventory or contact representatives.
• Telehealth platforms connecting patients with clinical support staff.
• Automated reminder systems for medication dosing and appointment scheduling.

While technology adoption in patient support programs remains relatively modest, digital solutions offer potential advantages including scalability, real-time intervention, and enhanced data capture for program optimization. However, technology must complement rather than replace human interaction, as personal connection with case managers and clinical educators appears to be a key driver of program effectiveness.

Evidence of Clinical and Economic Impact

Adherence and Persistence Outcomes

Multiple studies demonstrate that patient support programs significantly improve medication adherence and persistence. In a large real-world study of 2,268 patients receiving adalimumab for various autoimmune conditions, those participating in a comprehensive patient support program demonstrated:

• 29.3% higher medication adherence measured by proportion of days covered (64.8% vs 50.1%, p<0.0001)
• 22.0% lower discontinuation rate (51.4% vs 65.9%, p<0.0001)
• 62% longer median time to discontinuation (350 days vs 216.5 days)
• Significantly higher proportion achieving 80% adherence threshold (43.7% vs 25.7%)

These findings are consistent across multiple therapeutic areas and program designs. A review of forty-one patient support programs serving 22,833 patients with chronic diseases found that programs employing frequent touchpoints with trained medical professionals showed improved adherence, better disease control, lower hospitalization rates, and reduced disease activity.¹⁰

The improvement of adherence is clinically meaningful. For chronic disease management, the 80% adherence threshold is widely recognized as necessary to achieve therapeutic benefit. Programs that help 43.7% of patients achieve this threshold versus 25.7% without support represent a substantial increase in the proportion of patients receiving clinical benefit from therapy.

Healthcare Cost Impact

Perhaps most compelling from a system perspective, patient support programs demonstrate ability to reduce overall healthcare costs despite increased pharmaceutical expenditure. The adalimumab study found that program participants experienced:

The 29.2% reduction in all-cause medical costs and 35% reduction in disease-related medical costs substantially outweigh the 12.2% increase in drug costs. The primary driver of medical cost savings was reduction in inpatient hospitalizations, which decreased from $7,799 to $3,687 (p=0.002) for all-cause admissions and from $5,064 to $2,008 (p=0.003) for disease-related admissions.

This cost offset pattern—higher drug spending offset by lower medical spending—aligns with value-based care principles. By ensuring consistent therapy use and better disease management, patient support programs prevent the acute exacerbations and complications that drive hospital admissions and emergency department visits.

Quality of Life and Patient-Reported Outcomes

Beyond clinical and economic measures, patient support programs demonstrate impact on quality of life and patient satisfaction. Through multiple studies, participants reported:¹⁰

• Better disease control and symptom management
• Increased confidence in managing their disease.
• Greater satisfaction with care coordination
• Reduced anxiety about medication administration and side effects
• Improved ability to maintain normal daily activities.

Quality improvements appear to result from the combination of clinical support, reduced financial burden, and psychological reassurance that comes from having dedicated support resources. Patients enrolled in programs with regular nurse or pharmacist contact reported feeling more connected to their care team and better equipped to manage their condition independently.

In the next part of this report, Anbil and Khot discuss what makes patient support programs succeed, where the industry stands today, the challenges still facing these programs, and what's next for manufacturers, pharmacies, providers and payers looking to build one that works.

References

1. Vikas Kini and P. Michael Ho, "Interventions to Improve Medication Adherence: A Review," JAMA, Vol. 320, No. 23 (2018): 2461-2473. https://pubmed.ncbi.nlm.nih.gov/30561486/
2. Soeren Mattke, Lisa Klautzer and Tewodaj Mengistu, "Medicines as a Service: A New Commercial Model for Big Pharma in the Post Blockbuster World," RAND Corporation, 2012. https://www.rand.org/pubs/occasional_papers/OP381.html
3. Boston Consulting Group, "The Hidden Epidemic: Finding a Cure for Unfilled Prescriptions and Missed Doses," 2003.
4. Herma H. Fidder, Maartje M.J. Singendonk, Mike van der Have, et al., "Low Rates of Adherence for Tumor Necrosis Factor-alpha Inhibitors in Crohn's Disease and Rheumatoid Arthritis: Results of a Systematic Review," World Journal of Gastroenterology, Vol. 19, No. 27 (2013): 4344-4350. https://pmc.ncbi.nlm.nih.gov/articles/PMC3718902/
5. Institute of Medicine, "Leadership Commitments to Improve Value in Health Care: Finding Common Ground Workshop Summary," The National Academies Press, Washington, D.C., 2009. https://nap.nationalacademies.org/catalog/12563/leadership-commitments-to-improve-value-in-health-care-finding-common
6. Andreas Ucci, Giovanni Vanoli, Chiara Verri and Ben Falk, "Evolving the Product Launch Paradigm: How to Successfully Manage a Product Launch to Maximize Returns," Deloitte, 2018. https://www2.deloitte.com/ch/en/pages/life-sciences-and-healthcare/articles/evolving-the-product-launch-paradigm-in-pharma.html
7. McKesson, "Why Are Patient Support Services Critical for Your Drug Launch?" 2018. https://biologics.mckesson.com/
8. Diana Brixner, David T. Rubin, Philip Mease, Manish Mittal, Harry Liu, Matthew Davis, Arijit Ganguli and A. Mark Fendrick, "Patient Support Program Increased Medication Adherence With Lower Total Health Care Costs Despite Increased Drug Spending," Journal of Managed Care & Specialty Pharmacy, Vol. 25, No. 7 (2019): 770-779. https://pmc.ncbi.nlm.nih.gov/articles/PMC10398065/
9. Hong Tan, Jane Yu, David Tabby, Andrea Devries and Jeffrey Singer, "Clinical and Economic Impact of a Specialty Care Management Program Among Patients With Multiple Sclerosis: A Cohort Study," Multiple Sclerosis, Vol. 16, No. 8 (2010): 956-963. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923414/
10. Matthew Lamkin and Carl Elliott, "Curing the Disobedient Patient: Medication Adherence Programs as Pharmaceutical Marketing Tools," Journal of Law, Medicine & Ethics, Vol. 42, No. 4 (2014): 492-500. https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/article/abs/curing-the-disobedient-patient-medication-adherence-programs-as-pharmaceutical-marketing-tools/180C860D9BF62C69EEB58925CFAD15DB

Disclaimer: The views expressed in the article are those of the authors and not of the organizations they represent.